Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083899 | 1.00 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL3284285 | 1.00 | CYP3A4 (0.37) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL3283595 | 0.83 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL12083740 | 0.83 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL12083837 | 0.82 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL51896 | 0.82 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL3282951 | 0.82 | SMYD2 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL3282942 | 0.82 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL3787819 | 0.82 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL3282941 | 0.82 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258126-B2 | Vitamin D3 analogues for the prevention and treatment of bone disorders | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20100160455-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2010-06-24 | — | — | US | disclosed |
| US-7704986-B2 | 5-(((3-((4-Hydroxy,1,5-dimethylhexyl)-2,2,3-(trimethyl)cyclopentyl)-2-propenylidene)cyclohexane-1,3-diol; induce bone matrix formation; mineralization without hypercalcemia; side effect reduction; bone disorders; osteomalacia, renal osteodystrophy, Paget's disease and osteoporosis; skin disorders | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1809599-B1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | LEUVEN K U RES & DEV (BE) | 2008-12-10 | — | — | EP | disclosed |
| US-20080032955-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160455-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | VDR, CYP24A1, CYP2R1 | CYP3A4 3675/4885HTT 3922/4885SMN1; SMN2 2106/4885 |
| US-20080032955-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | VDR, CYP24A1, CYP2R1 | CYP3A4 3675/4885HTT 3922/4885SMN1; SMN2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.